Previous 10 | Next 10 |
2023-08-04 15:59:06 ET Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Conference Call August 4, 2023 08:30 ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder an...
2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...
2023-08-04 06:03:20 ET Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q2 Non-GAAP EPS of $0.19 beats by $0.09 . Revenue of $599M (+7.2% Y/Y) beats by $33.89M . FY23 Outlook: Net revenue of $2.3B-$2.4B from prior guidance of $2.25-$2.35B Adj EPS of...
‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Fu...
2023-08-03 14:20:38 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is $0.10 (-47.4% Y/Y) and the consensus Revenue Estimate is $565.11M (+1.1% Y/Y). Over the la...
- Represents three high-value medicines across complex dosage forms Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Adm...
2023-07-10 08:00:00 ET Summary A Complete Response Letter from the FDA temporarily tanked AMRX stock. New launches and established products should contribute to Amneal Pharmaceuticals' Q2 growth. A generic to blockbuster sets Amneal up nicely for Q3 and onward. July ...
NEW YORK, NY / ACCESSWIRE / July 9, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX). Investors who purchased Amneal securities are encouraged to obtain additional infor...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2023 financial results on Friday August 4, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on Aug...
2023-07-05 13:23:58 ET Shares of Amneal Pharmaceuticals (NYSE: AMRX) were down more than 13% as of 12:45 p.m. ET on Wednesday after the pharmaceutical company announced both positive and negative news regarding its clinical pipeline. The stock is still up more than 30% this year...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NYSE Market:
Amneal Pharmaceuticals Inc. Class A Website:
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...